

as said tumor cell, of eliciting an inflammatory immune response against the tumor of said human.--

E1
Sub
FS

-- 40. A composition comprising a haptenized syngeneic human tumor cell, said haptenized tumor cell substantially in a no growth phase and having the property, when administered with an adjuvant to a human suffering from a malignant tumor of the same type as said tumor cell, of eliciting a delayed-type hypersensitivity response to the tumor of said human.--

-- 41. A method of eliciting an inflammatory immune response to a tumor of a human comprising administering to said human a composition comprising a therapeutically effective amount of a haptenized syngeneic human tumor cell substantially in a no growth phase and an adjuvant, wherein said human suffers from a malignant tumor of the same type as said tumor cell, and measuring said inflammatory immune response.--

-- 42. A method of eliciting a delayed-type hypersensitivity response to a tumor of a human comprising administering to said human a composition comprising a therapeutically effective amount of a haptenized syngeneic human tumor cell substantially in a no growth phase and an adjuvant, wherein said human suffers from a malignant tumor of the same type as said tumor cell, and measuring said delayed-type hypersensitivity response.--

43. A composition comprising a haptenized syngeneic human tumor cell, said haptenized tumor cell substantially in a no growth phase and having the property, when administered with an adjuvant to a human suffering from a malignant tumor of the same type as said tumor cell, of eliciting an inflammatory immune response against the tumor of said human wherein said tumor is not melanoma.--

44. A method for treating a malignant tumor in a human patient comprising administering to the patient a composition comprising a therapeutically effective amount of a haptenized syngeneic human tumor cell substantially in a no growth phase and an adjuvant wherein said human suffers from a malignant tumor of the same type as said tumor cell, and thereby eliciting at least one of the following: an inflammatory immune response against the tumor of said human; a delayed-type hypersensitivity response against the tumor of said human and activated T lymphocytes that infiltrate the tumor of said human wherein said malignant tumor is not melanoma.--

45. The composition of claim 39 comprising a plurality of said tumor cells said tumor cells comprising a combination of intact and disrupted tumor cells.--

-- 46. A method according to claim 36 wherein said composition comprises a plurality of said tumor cells said tumor cells comprising a combination of intact and disrupted tumor cells.--

EI
Sub
FS
Conced

-- 47. A method of treating a malignant tumor in a human patient comprising administering to the patient a composition comprising a therapeutically effective amount of a haptenized syngeneic human tumor cell substantially in a no growth phase and an adjuvant wherein said human suffers from a malignant tumor of the same type as said tumor cell, and thereby eliciting at least one of the following: an inflammatory immune response against the tumor of said human; a delayed-type hypersensitivity response against the tumor of said human and activated T lymphocytes that infiltrate the tumor of said human and repeating said administration at least six times at spaced apart intervals. --

--48. A method of treating a malignant tumor in a human patient comprising administering to the patient a composition comprising a therapeutically effective amount of a haptenized syngeneic human tumor cell substantially in a no growth phase and an adjuvant wherein said human suffers from a malignant tumor of the same type as said tumor cell, and thereby eliciting at least one of the following: tumor regression and prolongation of survival. --

Please amend the claims as follows:

Please cancel claims 4 and 23.

Claim 2, line 1, following "tumor", insert --cell--;

E2
Sub
F2

22. A [pharmaceutical] composition comprising a [haptен modified] haptенized syngeneic human tumor cell, said haptенized tumor cell substantially in a no growth phase and having the property, when administered with an adjuvant to a human suffering from a malignant tumor of the same type as said tumor cell, of eliciting T lymphocytes that infiltrate the tumor of said human.

Claim 24, line 1, following "tumor", insert --cell--;

E3
Sub
F4

36. (Amended) A method of treating [cancer] a malignant tumor in a human patient comprising administering to [a] said patient a composition comprising a therapeutically effective amount of a haptенized [haptен modified] syngeneic human tumor cell substantially in a no growth phase and an adjuvant wherein said human suffers from a malignant tumor of the same type as said tumor cell, and eliciting activated T lymphocytes that infiltrate the tumor of said human.